Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, ...
ADS051 is the first and only MRP2 / FPR1 inhibitor to demonstrate favorable safety and tolerability with signals of clinical efficacy with relief from disruptive symptoms of inflammatory bowel disease ...
Schematic diagram (a) and photo (b) of the fabricated gas-filled hollow-core fiber phase modulator. (c) Measured loss spectrum and (d) transient response of the phase modulator. Credit: ...
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...
This study demonstrates a compact optical modulation platform that enables real-time, high-resolution spectroscopy using sub-MHz interleaved combs generated via chip-scale acousto-optic phase ...
Following favorable phase 1 data showing significant reductions in HBV DNA and RNA, the FDA has fast tracked pevifoscorvir sodium for chronic HBV infection.
Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results